WntResearch hereby presents its interim report with Foxy-5 phase 1-data
The interim report can also be found on WntResearch homepage: www.wntresearch.com
For additional information please contact:
Nils Brünner, CEO
Telephone: + 45 2614 4708
WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase 1 – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.